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Circadian clocks gate cellular proliferation and, thereby, therapeutically target availability within proliferative pathways. This
temporalcoordination occurswithinbothcancerous and noncancerous proliferatingtissues.Thetimingwithinthecircadian cycle
of the administration of drugs targeting proliferative pathways necessarily impacts the amount of damage done to proliferating
tissues and cancers. Concurrently measuring target levels and associated key pathway components in normal and malignant
tissues around the circadian clock provides a path toward a fuller understanding of the temporal relationships among the
physiologic processes governing the therapeutic index of antiproliferative anticancer therapies. The temporal ordering among
these relationships, paramount to determining causation, is less well understood using two- or three-dimensional representations.
We have created multidimensional multimedia depictions of the temporal unfolding of putatively causative and the resultant
therapeutic eﬀects of a drug that speciﬁcally targets these ordered processes at speciﬁc times of the day. The systems and methods
used to create these depictions are provided, as well as three example supplementary movies.
Copyright © 2009 Jamil Singletary et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
1.1. Daily Temporal Organization. Circadian organization
of living organisms is ubiquitous. Within these organisms,
circadian rhythms in synthetic, metabolic, and proliferative
functions characterize all organs, tissues, and cells. This
temporal organization is endogenous and conferred at all
levels of biological integration. The mammalian central cir-
cadian clock, residing in the suprachiasmatic nuclei (SCN),
sets circadian clocks throughout the body through auto-
nomic nervous connections, SCN-orchestrated endocrine
secretions, and complex SCN-inﬂuenced neurobiological
behavior patterns such as human nightly sleep and daily
activity [1–3]. Each cell in the body resonates with its
own circadian orientation, determined by the relationship
between the central time keepers’ and its own molecular
circadian clockwork [4–6].
The molecular timekeeping components and mecha-
nisms of the central and peripheral circadian clocks are
apparently identical and comprised of the coordinated
expression of some nine core circadian clock genes [6].
These core clock genes function in two linked feedback
loops—one positive, the second negative. Traverse of these
loops requires approximately 24 hours, creating a cellular
circadian pacemaker, in principle, akin to the sinoatrial node
in the heart. The phase and output of each peripheral clock
are unique to that speciﬁc tissue. The time structure of
each tissue clock is oﬀset characteristically for that tissue
from the central SCN-based circadian time structure. There
is evidence that each tissue coordinates most of its key2 International Journal of Biomedical Imaging
tissue-speciﬁc functions during each day through peripheral
circadian clock gating of a unique set of tissue-speciﬁc
circadian clock-controlled genes. At the gene expression
level, these circadian clock-controlled genes comprise ﬁve to
ten percent of the genome within each tissue [7].
The processes linked to the clock and the clock-
controlled genes are unique for each tissue. For example,
the liver organizes albumin synthesis, bile metabolism,
and detoxiﬁcation pathways within each day, while the
bone marrow and gut cells most prominently order cell
proliferation [8, 9]. When the liver is injured or resected,
however, hepatocyte regenerative proliferation is promptly
induced. This “on-demand” liver cell proliferation cassette
is tightly gated during each day by the identical clock
and clock-controlled genes that order proliferation in other
constitutively dividing tissues [10, 11].
1.2. Cancers Tell Time. Cancers in human beings and mice
are characterized by abnormal balance among cancer cell
proliferation, dormancy, and apoptosis. Since these physio-
logic states are clocked within each normal tissue, it is likely
that the development of cancer requires some disordering of
these clock-controlled states [12]. We have been surprised,
therefore, to learn that cancer cell proliferation still remains
tightly circadian-controlled in some human and mouse can-
cers [13, 14]. This temporal circadian organization of cancer
cellproliferationprovidesatherapeuticopportunityforopti-
mally timed cancer treatments to diminish side eﬀectsaswell
as to maximize anticancer activity in cancer patients [15].
1.3. Cancer Control Depends upon Treatment Timing. Since
many anticancer agents target proliferative pathways and
since cancer cell proliferation is circadian-rhythmic, anti-
cancer drug target availability within living cancer cells is
necessarily largely organized during each day. Randomized
clinicaltrialshavedemonstratedthatthiscircadianorganiza-
tion is evident even among genetically and environmentally
distinct cancer patients and can be used to improve the
outcome of cancer treatment. The judicious timing of
antiproliferative anticancer agents during the day resulted
in improved survival of women with metastatic ovarian
cancerandincreasedmetastaticcoloncancerobjectivetumor
response frequency [16, 17]. At the same time, optimal drug
timing diminishes the toxicity of these agents to the host gut
and bone marrow several fold [18, 19]. These therapeutic
advantages accrue despite the fact that the patients studied
in these randomized clinical trials and their cancers are
geneticallydistinctfromoneanotheranddespitethefactthat
patients with advanced cancer are ill.
2. Methods
A series of experiments was performed in 10- to 14-week
old CD2F1 female mice, kept on a 12-hour light: 12-hour
dark light regimen from birth. Time of day is referred to
as Hours After Lights On (HALO). Tumors were established
by transplantation, subcutaneously injected into the mouse
ﬂank with 5 × 105 viable meth-A sarcoma cells (provided by
the laboratory of Dr. Lloyd Old). When tumor nodules were
palpable, tumors were measured daily. When these tumors
averaged 500mm3 in volume, mice were either: (a) killed
at one of six equispaced consecutive times of day (every
4 hours) to harvest tumor and host tissues, or (b) treated
with intravenous 5-ﬂourouracil (5-FU) chemotherapy drug
at an eﬀective dose at one of these same six times of day.
Daily tumor measurements were continued and mice were
followed until death [20].
These tumor-bearing mice killed around the clock had
bone marrow, intestinal epithelium, and tumor tissues
removed, bisected, and stored at −80◦C. The other half of
bisected tumors were ﬁxed in 10% buﬀered formalin for
24 hours and embedded in paraﬃn for subsequent staining
and microscopic examination and immunohistochemical
analysis. Thymidylate synthase (TS), an enzyme which, in
the presence of folate and substrate, produces thymidylate,
without which DNA cannot be synthesized, is the primary
target of 5-FU antiproliferative eﬀect. TS message, protein,
and enzymatic activity were each measured in intestinal
mucosa, bone marrow, and tumor samples obtained every
4 hours around a 24-hour period. Mitotic index, growth
factor VEGF protein content, clock protein BMAL-1 nuclear
and cytoplasmic content, and WEE1 protein (which gates
mitosis) content were also measured in every tumor sample.
Thetumor-bearingmicetreatedwith5-FUhadmeasure-
ments of daily serial tumor size, tumor disappearance rates,
and survival assessments to determine therapeutic eﬀects.
5-FU toxicity to healthy host cells was assessed by body
weight fall and recovery, white blood cell fall and recovery,
and perianal swelling (GI toxicity). A toxic-therapeutic
index (TI) was then calculated for each 5-FU-treated mouse
by combining the resulting drug toxicity to the host and
tumor therapeutic eﬃcacy scores. High TI values indicated a
simultaneous occurrence of low host 5-FU toxicity with high
anti-tumor therapeutic eﬀects. Low TI values indicated high
host 5-FU toxicity and low anti-tumor therapeutic eﬀects.
These measurements allowed us to determine the circa-
dian relationships among tumor growth, relevant tumor cell
clock function, 5-FU target availability in normal and cancer
tissues, and the circadian organization of the resultant 5-FU
therapeutic index (anticancer eﬃcacy and bone marrow and
gut toxicity).
2.1. Multidimensional Processes. Movies were created in the
form of 3-dimensional (3D) contour plots of three potential
causallyrelevantfactorsatatimeusingbivariateinterpolated
values through Proc G3grid (SAS version 12, Cary, NC). The
procedure creates a data set where the horizontal (x)a n d
vertical (y)variablevaluesformacompletegrid,anditinter-
polates the value of the depth (z) variable for each point on
the x-y plane. Assuming that the relationship between two
times of day (HALO) measurements is linear, data obtained
from two consecutive times of day (e.g., 2 and 6 HALO) were
thenlinearlyinterpolatedtocreatedatathatspanaboutevery
8 minutes between these two times of actual measurement.
In order to interpolate these data points, the following
formula was used:
H2 − H1
n
+P1. (1)International Journal of Biomedical Imaging 3
In Formula (1), H1 refers to the value at a marked
(measured) HALO point, H2 refers to the following data
valueatthenextmarkedHALOpoint(4hourslater),nrefers
tothenumberoftimepointstobeinterpolated,and P1 refers
to the data value from the previous time point (8 minutes
prior). For these sets of data, 30 was chosen as the number
of data points, interpolated between each actual physical and
biochemical measurement.
Upon completion of the linear interpolation method, the
end result is a spreadsheet of values that span 121 rows and
181 columns of data values for each of these biologically
relevant variables. We then use Co-Plot Software (Monterey,
CA) tocreate3Dgraphs, creating an8-minute interval frame
over a 24-hour span which is sequentially displayed to create
movies depicting the 3D relationship over circadian time.
We have created three movies visualizing the relation-
ships of an undulating surface changing over the 24-hour
circadian cycle, comprised of the beating circadian clock as
created from quantitative measurement of BMAL-1 clock
protein in the tumor cell nucleus where it acts to keep
time; the maximum amount of tumor shrinkage occurs as
a result of circadian-timed 5-FU administration; the 5-FU
Toxic-Therapeutic Index (TI) with (1) cell DNA replication,
(2) cancer cell division and growth, and (3) 5-FU target,
toxicity, and therapeutic eﬀects. The undulating 3D surface
relationshipsturnfromblue(best),topurple(intermediate),
to red (worst), to purple, to blue as TI changes rhythmically
over circadian time. Because the rates of change of these rela-
tionships are also rhythmically changing throughout each
day,amusicalscoreisaddedintwoacousticdimensions.The
melody cycles once throughout each completed circadian
cycle. The beat/cadence of the musical score quickens as the
changes in the relationships over these 24 hours accelerate
and slows as they decelerate.
Finally, inspirational major chords accompany favorable
circadian stages while melancholy minor chords accom-
pany biomedically unfavorable relationships. Harmonically-
favorable circadian stages are independently calculated by
quantifying the survival duration of tumor-bearing mice
treated at six circadian stages with 5-FU. This shape, color,
and audio scheme concurrently depict the relationships
among tumor cell circadian clock function, circadian tumor
cell availability of the target of 5-FU, TS activity (TSA),
the circadian therapeutic pattern of 5-FU induced tumor
shrinkage, the TI of 5-FU treatment and the rate of
change of these relationships within the day, and the overall
survival beneﬁt for tumor-bearing mice resulting from 5-FU
treatment at six times of day.
3. Results
3.1. Relevant Previous Findings. We have previously
described the chain of events linking cancer cell clock
proteins, cancer cell DNA synthesis, proliferation, TSA, and
5-FU TI to explain the dependence of cancer outcome on
circadian timing of 5-FU [20]. We have shown that despite
the fact that cancers often exhibit deregulated cellular
proliferation, cancers maintain high amplitude circadian
rhythms in their growth, DNA synthesis, and mitosis.
Circadian-timed tissue acquisition allowed us to determine
circadian relationships among tumor size, relevant clock and
clock-controlled proteins, and 5-FU drug target availability
(e.g., TS) in normal and cancer tissues. A separate study of
circadian-timed 5-FU drug administration allowed us to
determine circadian relationships among drug-induced host
bone marrow and gut toxicity, tumor shrinkage, and the
balance between 5-FU toxicity and anti-tumor eﬀects (e.g.,
TI). The time of day was recorded as Hours After Lights On
(HALO). The time of day (HALO) at which tumor TSA is
low, 5-FU TI is high (See supplementary Tables 1 and 2 in
Supplementary Material avialable at doi:1155/2009/231539).
At this time of day, tumor WEE-1 and nuclear BMAL1 levels
are higher (Supplementary Table 3). Conversely, HALOs at
which tumor TSA is high, 5-FU TI is low. At these times,
t u m o rW E E - 1a n dn u c l e a rB M A L 1a r el o w e r[ 20].
3.2. 3-D Movies Uncover Diurnal Relationships. Understand-
ing the temporal relationships of the circadian dynamics
of cancer and normal cell clock function, DNA synthetic
activity, mitosis, tumor growth rate, and cancer drug ther-
apeutic index is challenging. We have therefore created a
series of multidimensional motion pictures to describe these
predictable rhythmic relationships; each endpoint depicted
is statistically signiﬁcantly modulated during circadian time
[20]. These movies show the relationship among molecules
key to DNA synthesis, cell division and susceptibility of
tumor and normal tissue to the eﬀects of 5-FU. Each movie
depicts, in two dimensions, the circadian diﬀerences in
tumor volume or the toxic therapeutic index of 5-FU and
tumor nuclear BMAL-1 clock protein content. Also added
is a measurement of time kept by the external environment
through the rising and setting of the sun and the clock in the
left-hand corner.
3.2.1. Cancer Cell DNA Replication. DNA synthesis occurs
during the S phase of the cell cycle and is accompanied
by an increase in TSA. TS is the enzyme inhibited by 5-
FU. Supplementary Movie 1 (see also Figure 1) shows the
relationship of tumor size and tumor TS message, protein,
enzyme activity, and tumor nuclear BMAL1 within the
circadian cycle. This movie depicts that a high concentration
of TS mRNA precedes high TS protein and TSA, which is
expectedasproteinisprecededbymRNA.At2HALO,tumor
mRNA concentration is at its peak which consequently leads
to the maximum tumor TS protein at the next HALO (6
HALO), which is associated with the highest amount of TSA
at 6 HALO. Then at 6 and 10 HALO, tumor TS mRNA levels
decrease leading to lower tumor TSA levels at 10 and 14
HALO.TumorTSApeaksat6and22HALO,whichcoincides
with or just precedes the peak in tumor size, linking tumor
growth and DNA synthesis throughout the circadian cycle.
Nuclear BMAL1 daily rhythm is shown in the bottom panel
as a measure of the circadian clockwork in tumor cells. The
best 5-FU therapeutic outcome is achieved when tumor TSA
levels are low (also see Figure 3). At 2 and 14 HALO, tumor
size is low, which is also when nuclear BMAL1 is high.4 International Journal of Biomedical Imaging
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Figure 1: Snapshot of Supplementary Movie 1. The cytotoxicity of 5-FU (5 Fluorouracil), an agent targeting thymidylate synthase (TS), is
greatest when TS activity is the lowest. Both message and protein are necessary precursors for TS enzyme activity. Average tumor size is the
lowest between 2 and 6 Hours After Lights On (HALO) when TS message and protein are both present. TS activity rises modestly as tumor
size increases. TS message then fades as TS protein persists, TS activity declines and tumor size decreases. TS activity then spikes followed
by tumor size and TS activity recession with residual TS message and protein. Times of day associated with the lowest tumor cell enzyme
activity are the times of day associated with greatest 5-FU tumor cell anticancer activity. Times of day associated with highest tumor cell
TS activity correspond to times of day of greatest tumor cell resistance to the cytotoxic eﬀects of 5-FU. Tumors can thereby be expected to
be most resistant to 5-FU in the middle of the daily dark/activity span (18 HALO) and most sensitive to 5-FU in the middle of the daily
light/sleep span.
3.2.2. Cancer Cell Division and Growth. WEE-1 is a clock-
controlled protein and inhibits and gates mitosis at the G2M
interface of the cell cycle. Supplementary Movie 2 (see also
Figure 2) shows the relationship of tumor size to tumor
mitotic index (vertical axis), tumor cell VEGF (horizontal
axis) and tumor WEE-1 (oblique axis) over the circadian
cycle. Throughout the circadian cycle, tumor WEE-1 and
tumor mitotic index (MI) have an inverse relationship.
VEGF is a clock-controlled growth factor that promotes
cancer growth. During the circadian cycle, tumor VEGF
levels vary in parallel to tumor MI. This movie shows that
as tumor WEE-1 increases, reaching its maximum in early
activity phase (14 HALO), VEGF begins to increase and then
drops, which is accompanied by a decrease in tumor MI. A
decrease in WEE-1 during the late activity/ early sleep span
is accompanied by a sudden surge in VEGF, at which time
tumor MI levels increase. Poor 5-FU therapeutic outcomes
are found at high tumor MI levels at 10 and 22 HALO, at
which time tumor nuclear BMAL1 is lower (Figure 3).
3.2.3. 5-FU Eﬀects on Both Tumor and Normal Cells. Supple-
mentary Movie 3 (see also Figure 3) depicts the relationship
of 5-FU toxic-therapeutic index (TI) to the amount of drug
target (e.g., TSA) in the gut epithelium cells, nucleated boneInternational Journal of Biomedical Imaging 5
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Figure 2: Snapshot of Supplementary Movie 2. WEE-1 is known to prevent or gate mitosis at the G2M interface of the cell cycle. VEGF is
known to promote cancer growth and cancer cell division. Throughout the day as WEE-1 increases, no mitosis occurs. As WEE-1 decreases,
mitosis appears and gradually increases to a high level. Concurrently, VEGF content of the same tumor cell increases markedly.
marrow cells, and tumor cells. The most favorable outcome
(high TI) is when tumor TSA is at its minimum, allowing
tumor TS to be more easily inhibited by 5-FU. 5-FU will also
be harmful to the host when TSA levels of healthy gut and
bone marrow cells are low. Thus, the best therapeutic eﬀect
(harmful to the tumor cells but little eﬀect on healthy cells)
of 5-FU occurs when TSA in tumor cells is relatively low, at
a time when TSA in gut epithelium and bone marrow cells
are relatively high. TI is calculated by considering both the
toxicity of 5-FU to the host (absolute AUC WBC counts,
absolute AUC body weight, and presence or absence of
perianal swelling) and anti-tumor therapeutic eﬀects (tumor
remission, decrease in tumor size, and survival). A higher
value of TI demonstrates low host drug toxicity along with
high tumor therapeutic eﬀects. This movie depicts that the
best outcome (highest TI level) is at 14 HALO and at 2
HALO. At 14 HALO, tumor TSA is at a minimum and,
although small intestine TSA and bone marrow TSA are not
at their maximum levels which occur at 6 HALO and 18
HALO respectively, they are still relatively high, shielding
them from the eﬀects of 5-FU. Thus, at 14 HALO, 5-FU
creates the largest diﬀerence between toxicity to the tumor
cells versus toxicity to gut and bone marrow cells. Figure 3
demonstrates that at 22 HALO, tumor TSA is high, which
leads to a low TI. As shown, a high tumor TSA level is also
associated with low nuclear BMAL1 levels. Depicted in blue
in the middle graph is where TI is at a maximum, which
occurs at 14 HALO with high levels of gut cell and bone cell
TSA and concurrent low tumor TSA.
4. Discussion
Being able to visualize and hear the diurnal/nocturnal
dynamics of the host tissues and the cancer demonstrates
how and why the circadian timing of 5-FU determines
both its eﬃcacy and its toxicity. These relationships are6 International Journal of Biomedical Imaging
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61 01 41 82 2 2
HALO of 5-FU treatment
0
1
2
3
T
o
x
i
c
-
t
h
e
r
a
p
e
u
t
i
c
 
r
a
t
i
o
61 0 1 41 8 22 2
B
M
A
L
-
1
7
6
4
3
2
0
5
HALO of Sacrifice
200
150
100
50
T
S
A
-
t
u
m
o
r
 
(
p
M
/
m
i
n
/
m
g
)
300
250 200
150 100 50 10
20 30 40 50 60
TSA SI (pM/min/mg)
TSA-marrow (pM/min/mg)
(d) Shown at 14 HALO
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Figure 3: Snapshot of Supplementary Movie 3. The relationship between 5-FU Target and Toxic-Therapeutic ratio proceeds throughout
the day indicating time of day association with low tumor thymidylate synthase activity are concurrent with times of day of the greatest
anticancer activity. Times of low thymidylate synthase in bone marrow and gut cell are those same times of day associated with the greatest
gut damage and bone marrow damage. Toxic-therapeutic ratio is maximum at times of day of relatively low tumor thymidylate synthase
activity and relatively high bone marrow and gut TSA.
clinicallyrelevantandhavealreadybeenproveninmetastatic
colorectal cancer patients [21, 22].
Obviously, our chosen methods have limitations. Linear
interpolations between four-hourly observations make the
unwarranted assumption that changes between the six
measured circadian phases is unidirectional and continuous.
These assumptions must be kept in mind while viewing the
movies provided.
The data presented here contains a plethora of informa-
tion that must be understood concurrently. Such a method
can be useful in displaying other data that also change and
evolve over time, linearly, rhythmically, or chaotically. By
introducing other variables such as color scheme, music, and
internal and environmental time measurements, we are able
to present other dynamical cues.
Creating such a multimedia display aims to arouse each
of the senses of the viewer to enhance understanding. We,
herein, have developed a unique way to take a large number
of ordered raw data and convert these into meaningful visual
and aural experiences. In doing this, many obstacles have
been encountered. Multiple pieces of software had to be used
in order to optimally create these movies and integrating
them was a challenge.
Themajordrawbacksofusingmultiplepiecesofsoftware
are that our data must be converted to diﬀerent ﬁle types
throughout the entire process. At each such step, this creates
potential for error. Therefore, we have begun to create a
purpose built software package called the Temporal Data
Transformer. The goal of the Temporal Data Transformer
will be an easier, more eﬀective “automatic” creation ofInternational Journal of Biomedical Imaging 7
such movies directly from the time coded temporal data
stream.
Commentary. Themostimportanttestofcausalityistempo-
rality.Inorderforaneventtocauseorcontributetothecause
ofanotherevent,thecausativeeventmustprecedethecaused
event. All biological processes are precisely ordered in time.
This temporal organization is commanded by evolution for
thermodynamic reasons, translated practically as essential
biological economy and parsimony.
Time is measured solely by triangulation between and
among recurrent events. Events and milieu favorable to the
occurrence of complex biological events require opportuni-
ties for their recurrence as a prerequisite for life. Without
modulation of time’s merciless arrow by biological systems,
life would be an impossibility. If biological systems truly
could not step into the same river twice, life, at least as we
know it, could not exist.
Theseopportunities forrecurrencehavebeenguaranteed
by evolution in response to the time structures of our near
cosmos. Cosmic cycles of profound regularity have been
borrowed by all living things and used to organize all life
processes rhythmically. The circadian frequency range is the
most thoroughly explored. We and others have shown that
cellular proliferation is one such complex life process that is
tightly organized at the cellular and tissue levels within each
day.Wehaveshownthistobetrueincancercellsandtumors.
This profound rhythmic circadian organization of all
cellular events essential for proliferation makes the search for
temporality complex but impossible if this time structure is
ignored. If the cyclical nature of this essential aspect of life is
ignored in favor of a linear approach, causality relationships
will appear where they do not exist and be unapparent
where they clearly exist. This is especially dangerous where
experiments supposedly determining cause-and-eﬀect are
done outside of a resonating living organism.
We have begun to address this indirect complexity by
makingmeasurementsofproliferationinkeyhostandcancer
tissues, around the circadian clock, and then displaying
the resultant relationships visually and aurally, looped over
the entire circadian span. We believe that this approach,
which can be duplicated for any rhythmic time-coded
data, may prove useful to those who wish to under-
stand complex interactive cause-and-eﬀect relationships that
characterize all life including therapeutically relevant host-
cancer relationships—the complex symphony of life without
melody, tempo, and rhythm in apparent cacophony.
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